ClinicalTrials.gg
CompletedNCT01686711Updated Aug 31, 2023

A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

A Phase 4 interventional study of AD-4833 15 mg and AD-4833 30 mg in Diabetes Mellitus, sponsored by Takeda. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
207
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing pioglitazone in Diabetes Mellitus — 4 open to participants now, 4 under way, none of them phase 3. Pioglitazone · Diabetes Mellitus.

Enrollment
21st of 55
207 · median 104
Started
2012
the only one that year
Phase 4
22 of 57
1 open now
Registered
48th of 57
by date
Lead sponsor
23 of 57
Takeda

Among the 57 studies testing pioglitazone in Diabetes Mellitus, this one is the 21st largest by enrollment of the 55 interventional ones that give a count, is the only one that started in 2012, is one of 22 in phase 4, and was the 48th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 57 studies testing pioglitazone in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing pioglitazone in Diabetes Mellitus, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
  • Those who can sign and date a written, form prior to the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  • Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc.
  • Others who are assessed to be ineligible for the study by the investigator or subinvestigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
207 participants (actual)

Study arms

  • Experimental
    SYR-322 25 mg , AD-4833 15 mg

    Drug: AD-4833 15 mg

  • Experimental
    SYR-322 25 mg , AD-4833 30 mg

    Drug: AD-4833 30 mg

  • Placebo comparator
    SYR-322 25 mg , AD-4833 placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Glycosylated Hemoglobin (HbA1c)

    Measurement of change in HbA1c (ratio of hemoglobin bound to glucose)

    Time frame: 16 weeks

07

Study locations

25 sites
  • Hirosaki-shi, Aomori, Japan
  • Kisaratsu-shi, Chiba, Japan
  • Matsuyama-shi, Ehime, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kitakyushu-shi, Fukuoka, Japan
  • Kurume-shi, Fukuoka, Japan
  • Fukuyama-shi, Hiroshima, Japan
  • Hiroshima-shi, Hiroshima, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Koga-shi, Ibaraki, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Miyazaki-shi, Miyazaki, Japan
  • Suita-shi, Osaka, Japan
  • Koshigaya-shi, Saitama, Japan
  • Otsu-shi, Shiga, Japan
  • Chiyoda-ku, Tokyo, Japan
  • Chuo-ku, Tokyo, Japan
  • Itabashi-ku, Tokyo, Japan
  • Meguro-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Ohta-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Toyama-shi, Toyama, Japan
  • Shimonoseki-shi, Yamaguchi, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2012
First posted
Sep 18, 2012
Start
Sep 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01686711
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 18, 2012
Start date
Sep 2012
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Aug 31, 2023

Study contacts

Study Director
study director · Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion